RP23-110D11.1 Inhibitors
RP23-110D11.1 inhibitors belong to a specialized class of chemicals that interact with a particular target identified by the genomic locus RP23-110D11.1. The nomenclature stems from a clone-based mapping system in genomic libraries, often used in reference to mouse genomic libraries, which can be utilized to pinpoint genetic sequences of interest. The inhibitors that fall under this category are designed to bind selectively to the protein product or the functional biological mechanism associated with this specific genomic sequence. By doing so, these inhibitors can modulate the activity of the protein or the pathway in which the protein is involved, leading to alterations in the biochemical processes within the cell.
The design and development of RP23-110D11.1 inhibitors require an in-depth understanding of molecular biology and chemistry. These inhibitors are typically small molecules that can fit into the active site or a regulatory region of the target protein, thereby affecting its function. The development process often begins with the identification of the protein structure associated with the RP23-110D11.1 sequence, which can be determined through methods such as X-ray crystallography or NMR spectroscopy. Subsequently, chemical compounds are either sourced from chemical libraries or specifically synthesized to interact with the target site. Through a series of iterative processes including structure-activity relationship (SAR) studies, the chemical entities are optimized for improved selectivity and potency with respect to the target. The resulting compounds are then rigorously tested in various assays to evaluate their interaction with the target and to determine their specificity in comparison to other related proteins or pathways.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Phenylarsine oxide | 637-03-6 | sc-3521 | 250 mg | $40.00 | 4 | |
Phenylarsine oxide is an organoarsenic compound that acts as an inhibitor of thiol-reactive enzymes. Given RP23-110D11.1's potential involvement in redox signaling due to its protein structure, this compound can bind to cysteine residues within the protein, disrupting its function by altering its redox state. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3Ks). If RP23-110D11.1 is involved in the PI3K/AKT/mTOR signaling pathway, wortmannin would indirectly inhibit RP23-110D11.1's activity by preventing the pathway's downstream signaling that might be critical for its function. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the AKT signaling pathway. If RP23-110D11.1 activity is AKT dependent, triciribine's inhibition of AKT phosphorylation and activation would result in the reduced functional activity of RP23-110D11.1. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases. Should RP23-110D11.1 be regulated by phosphorylation, staurosporine could inhibit those kinases responsible, thus indirectly reducing RP23-110D11.1 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another inhibitor of PI3K. Similar to wortmannin, if RP23-110D11.1 operates downstream of PI3K, inhibition by LY294002 would lead to a decrease in RP23-110D11.1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. If RP23-110D11.1 is part of the mTOR signaling cascade, rapamycin would indirectly lead to the decrease in its activity by inhibiting mTOR complex 1 (mTORC1). | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. If RP23-110D11.1 is regulated by p38 MAPK-mediated signaling, this compound would inhibit the kinase's activity, thus indirectly leading to decreased RP23-110D11.1 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, enzymes upstream of ERK in the MAPK pathway. If RP23-110D11.1's function is tied to ERK signaling, inhibition by U0126 would lead to its functional downregulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK pathway. If RP23-110D11.1 activity is modulated by JNK signaling, using SP600125 would indirectly inhibit RP23-110D11.1 activity by blocking JNK signaling. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). If RP23-110D11.1 is regulated through the cell cycle by CDK4/6, palbociclib would lead to a decrease in RP23-110D11.1 activity by halting cell cycle progression. | ||||||